Business
Pharma services contract with Artios Pharma
Pharma services contract with Artios Pharma.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n\n \n\n\n\nFor immediate release\n\n\n 25 May 2023\n\n\n\n \nANGLE plc (\"the Company\")\n \nPharma Services Contract Win\n \nParsortix DNA Damage Response Assays developed by ANGLE to be used for exploratory objectives in a Phase 1 clinical trial\n \nTrial expected to complete by year end 2024\n \nANGLE plc (AIM: AGL; OTCQX: ANPCY), a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence shortly.\n \nArtios is a clinical-stage biotech company pioneering the development of small molecule therapeutics that target the DNA Damage Response (DDR) process in order to treat patients with a broad range of cancers. Artios has an extensive DDR focused pipeline and strategic partnerships with global pharma companies.\n \nArtios selected ANGLE to develop immunofluorescence (IF) assays using its Parsortix system to detect two specific biomarkers expressed on circulating tumour cells (CTCs). The expression of the two biomarkers indicate the amount of DNA damage caused in a cell.\n \nThe markers can be observed in tumour tissue, but the availability of tumour tissue biopsy material is limited and cannot be repeated, emphasising the utility of CTCs obtained via liquid biopsy as an alternative means of assessing DNA damage. Artios is utilising longitudinal monitoring of expression of these biomarkers in CTCs harvested using the Parsortix system to assess the pharmacodynamic effects and treatment response to new DDR drugs.\n \nThe successful development of these DDR assays (high levels of both sensitivity and specificity were achieved) was technically challenging and a significant achievement. Artios will now utilise the two assays in a Phase 1 clinical trial scheduled to begin shortly and expected to complete around the end of 2024. ANGLE anticipates that these assays could be employed in larger, later stage clinical trials for the same compound and potentially in further trials for additional compounds in the customer's pipeline.\n \nANGLE can offer this CTC solution to the growing number of drug developers exploring the DDR pathway in drug trials. There are an estimat...